CardioGraft-MC® Decellularized Hemi-Pulmonary Patch

Download the files in the language of your choice
Instructions for Use
Product Specifications


CardioGraft-MC Decellularized Hemi-Pulmonary Patch is used for cardiac repair and reconstruction of the right ventricular outflow tract (RVOT).
  • Human Tissue: Closely resembles autograft; compliant, flexible, easy to handle and suture.
  • Resistant to Infection: Natural ability to resist infection.1-3
  • Convenient: Availability in various sizes to best fit the patient’s anatomy.
  • Decellularized: Patented Matracell® technology removes ≥99% of donor DNA.3
  • Clinically Effective: Lower potential for reoperation or intervention. Proven resistance to calcification and stenosis.1,2
  • Efficient: Potentially reduces operating room time and cost by reducing the rate of serious adverse events and reoperations.4
Clinical Application

Repair of the right ventricular outflow tract for:

  • Tetralogy of Fallot
  • Truncus Arteriosis
  • Transposition of the Great Arteries
  • Pulmonary Stenosis/Atresia
Frozen Description Sizing
DLHPA Left  Multiple options, varies by donor
DRHPA Right Multiple options, varies by donor
  1. Lofland GK, et al. Initial pediatric cardiac experience with decellularized allograft patches. Ann of Thoracic Surg, 2012;93:968-71.
  2. Hopkins RA, et al. Pulmonary Arterioplasty With Decellularized Allogeneic Patches. Ann of Thoracic Surg, Vol. 97, Issue 4, April 2014, Pages 1407-1412.
  3. LifeNet Health data on file: PQ-07-078.
  4. CardioGraft-MC (also known as Matracell®) Decellularized Cardiac Patch Allograft Cost-Effectiveness Analysis Musculoskeletal Clinical Regulatory Advisors, June 2014.
  5. LifeNet Health data on file: PQ-07-078.